Mantle Cell Lymphoma (MCL) Clinical Trials in Shanghai, Shanghai Municipality
2 recruitingShanghai, Shanghai Municipality, China
Showing 1–2 of 2 trials
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.75 enrolled29 locationsNCT07082686
Recruiting
Phase 2
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Mantle Cell Lymphoma (MCL)
Ruijin Hospital25 enrolled1 locationNCT07272499